Bioequivalence study of BAY 77-1931 orally disintegrating tablet
The primary objective of this study was to establish the bioequivalence of two different tablet formulations containing BAY77-1931. The secondary objectives of this study were to assess the safety and tolerability, as well as to Investigate the plasma lanthanum concentration after BAY 77-1931 ODT 500 mg administration.
- Japanese healthy male adult volunteers (age, 20-45 years; BMI, 17.6-26.4 kg/m2)
- Regular use of medicines including Chinese herbal drugs - Clinically relevant findings in the physical examination - Subject who cannot take the study drug appropriately (e.g. weak biting force, insufficient salivary flow)
Fukuoka, Japan, 812-0025
E-mail: [email protected]
Phone: Not Available
Bioequivalence study of BAY 77-1931 orally disintegrating tablet – randomized, open-label, two-way crossover study to establish the bioequivalence between BAY 77-1931 orally disintegrating tablet 500 mg and Fosrenol chewable tablet 500 mg administered in Japanese healthy male adult subjects